Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
References
Additional references
Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M, Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545‐55.
Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008;63(2):122‐8.
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed‐dose combinations improve medication compliance: a meta‐analysis. Am J Med. 2007;120(8):713‐9.
Bateman ED, Chapman KR, Singh D, D’Urzo AD, Molins E, Leselbaum A, et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research 2015;16(1):92.
Beeh KM, Burgel P‐R, Franssen FME, Lopez‐Campos JL, Loukides S, Hurst JR, et al. How do dual long‐acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease?. American Journal of Respiratory and Critical Care Medicine 2016;196(2):139‐49.
Calverley PMA. Minimal clinically important difference‐‐exacerbations of COPD. COPD 2005;2(1):143‐8.
Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: Optimizing synergy. European Journal of Pharmacology 2015;761(C):168–73.
Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta‐analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest 2016;149(5):1181‐96.
Calzetta L, Rogliani P, Ora J, Puxeddu E, Cazzola M, Matera MG. LABA/LAMA combination in COPD: A meta‐analysis on the duration of treatment. European Respiratory Review 2017;26(143):160043.
Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal 2008;31(2):416‐69.
Cazzola M, Molimard M. The scientific rationale for combining long‐acting & beta2‐agonists and muscarinic antagonists in COPD. Pulmonary Pharmacology 2010;23(4):257–67.
Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside.. Respiratory Medicine 2015;109(10):1305‐11.
Center for Disease Control. Chronic obstructive pulmonary disease among adults ‐ United States, 2016. www.cdc.gov/copd/index.html (accessed 1 Apr 2017).
Chapman KR, Bergeron C, Bhutani M, Bourbeau J, Grossman RF, Hernandez P, et al. Do we know the minimal clinically important difference (MCID) for COPD exacerbations?. COPD 2013;10(2):243‐9.
Farne HA, Cates CJ. Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD008989.pub3]
Global Initiative for Chronic Obstructive Lung Disease. From the global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD) 2017. //goldcopd.org (accessed prior to 3 November 2017).
Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax1987; Vol. 42, issue 10:773‐8.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self‐complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. American Review of Respiratory Disease 1992;145(6):1321‐7.
Martinez FJ, Rabe KF, Ferguson GT, Fabbri LM, Rennard S, Feldman GJ, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co‐suspension delivery technology in patients with COPD. Chest 2017;151(2):340‐57.
Polkey MI, Spruit M, Edwards LD, Watkins ML, Pinto‐Plata V, Vestbo JÃ, et al. Six‐minute‐walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. American Journal of Respiratory and Critical Care Medicine 2013;187(4):382‐6.
Puhan MA, Soesilo I, Guyatt GH, Schunemann HJ. Combining scores from different patient reported outcome measures in meta‐analyses: when is it justified?. Health and Quality of Life Outcomes 2006;4:94.
Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: A clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of Internal Medicine 2011;155:179‐91.
Sarai M, Sin D, FitzGerald JM, Aaron S. Long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD011282]
Schunemann HJ, Griffith L, Jaeschke R, Goldstein R, Stubbing D, Guyatt GH. Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. Journal of Clinical Epidemiology 2003;56(12):1170‐6.
Schunemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement properties and interpretability of the Chronic respiratory disease questionnaire (CRQ). COPD 2005;2(1):81‐9.
Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): A multicentre, randomised study. BMC Pulmonary Medicine 2014;14:178.
van Noord JA, Aumann J, Janssens E, Smeets JJ, Verhaert J, Disse B, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. European Respiratory Journal 2005;26(2):214–22.
Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2013;187(4):347–65.
Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomised, double‐blind, parallel‐group study. Lancet Respiratory Medicine 2013;1(3):199–209.
Wedzicha JA, Calverley PMA, Albert RK, Anzueto A, Criner GJ, Hurst JR, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal 2017;50(3):1602265.
Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun‐Niggli G, Worthy G. Relationship between FEV1 change and patient‐reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respiratory Research 2011;12:40.
World Health Organization. Global health estimates ‐ year 2015. www.who.int/mediacentre/factsheets/fs310/en/ (accessed 1 April 2017).
